Laura Zitella on Third-Line Treatment Considerations in Diffuse Large B-Cell Lymphoma
Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses third-line treatment options for patients with diffuse large b-cell lymphoma.
Combination chemotherapy with rituximab (Rituxan), known as R-CHOP, has been the standard of practice for diffuse large B-cell lymphoma for many years and is commonly used in many patients, explains Laura Zitella, MS, RN, ACNP-BC, AOCN. However, patients who do not respond to this chemoimmunotherapy treatment may progress to CAR T-cell therapy and other options in the second-line and beyond setting, such as loncastuximab tesirine (Zynlonta).
Zitella, a nurse practitioner at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, and associate clinical professor at UCSF school of nursing, also recently presented at PER®s Onco-Nurse Academy about safely administering Integrating Novel Therapies Across the DLBCL Care Spectrum.
In an interview with Oncology Nursing News®, Zitella highlights what treatment options exist for patients whose disease progresses beyond CAR T-cell therapy options, and the important considerations nurses should keep in mind with the available third-line agents.
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
May 8th 2024Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.
Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma
May 6th 2024Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.
Verification Nurse Provides ‘Significant Contribution to Patient Safety’ During Chemo Administration
May 1st 2024The role of a verification nurse can lead to several benefits, including the prevention of errors from reaching the patient, decreased workload, and potential cost savings from less drug waste.
